Global Neutropenia Pipeline Insights 2020 - Major Developments, Drugs and Players
Wednesday, August 12, 2020
DUBLIN, Aug. 4, 2020 /PRNewswire/ -- The "Neutropenia Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
PIPELINE HIGHLIGHTS
Neutropenia is one of the widely researched conditions during 2020 with 24 companies actively focusing on realizing pipeline's potential. Development of Neutropenia medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Neutropenia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Neutropenia.
Good progress is anticipated during 2020 and 2021 with Neutropenia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Neutropenia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
DRUG DEVELOPMENT PIPELINE OVERVIEW
The Neutropenia pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Neutropenia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
The competitive intelligence report on Neutropenia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Neutropenia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
DRUG PROFILES
Neutropenia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:
-- Current Status of Development including phase advancements, regulatory
approvals of phases, acquisitions, licensing and technology transfers,
product launches in various markets, and others.
-- Phase of development
-- Mechanism of Action
-- Route of Administration
-- Companies involved including originator, licensing companies, developer,
investors, and others
-- New molecular entity details
-- Orphan drug designation and other special status provided by regulators
COMPANY PROFILES
Both small size and large size pharmaceutical companies are investing their resources in Neutropenia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Neutropenia. Partnerships and acquisitions are also increasingly observed in the pipeline.
This research report presents an analysis of 24 Neutropenia companies including company overview, key snapshot, contact information, and their strategies on accelerating Neutropenia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.
Reasons to Buy
-- The current market conditions are forcing companies and investors
worldwide to prioritize their investments and accelerate pipeline
candidates only through careful quantitative assessment
-- This research work assists decision makers in pharmaceutical companies
towards successful pipeline development through critically evaluated
pipeline data
-- Buyers can identify most promising drug candidates for treatment of
Neutropenia
-- It allows users to strengthen their pipeline through acquisitions,
licensing and collaborations
-- Users can estimate possible delays in the delivery of pipeline or launch
of new products
-- Stay ahead of competition through understanding their pipeline
progression, strategies and outlook
-- The report details all the pipeline candidates under investigation in
various stages of development from Phase I through to Phase III to
enable business development managers to understand the impact of new
launches
-- Optimize your licensing and technology transfer strategies through
identification of prospect partners
Companies Analyzed
-- Apotex Inc.
-- BeyondSpring Inc.
-- Biocon Ltd.
-- Biocure Technology Inc.
-- Biosidus SA
-- Bolder BioTechnology
-- Cellerant Therapeutics Inc.
-- Chong Kun Dang Pharmaceutical Corp.
-- Cleveland BioLabs Inc.
-- CPL Biologicals Pvt. Ltd.
-- Dr. Reddy's Laboratories Ltd.
-- Emendo Biotherapeutics
-- Enzychem Lifesciences Corp.
-- Kashiv BioSciences
-- Lupin Ltd.
-- Merck & Co. Inc.
-- Mycenax Biotech Inc.
-- Nexgen Biosciences
-- Phoenicia Biosciences Inc.
-- Prolong Pharmaceuticals LLC
-- Siam Bioscience Co. Ltd.
-- Toko Pharmaceutical Industries Co. Ltd.
-- USV Pvt. Ltd.
-- X4 Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/k96lu8
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-neutropenia-pipeline-insights-2020---major-developments-drugs-and-players-301105565.html
SOURCE Research and Markets
|
|
|
|
|
 |
Asetek - Mandatory Notification of Trade | Jan 22, 2026
|
|
Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026
|
|
BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026
|
|
Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026
|
|
Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026
|
|
California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026
|
|
AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026
|
|
Immutable Announces First Co-Founder-Hosted Live Webinar: How to Dominate Your Steam Launch | Jan 22, 2026
|
|
Gemmy Alerts Customers: Fake Websites Target Holiday Decorators | Jan 22, 2026
|
|
Culture and tourism sectors thrive in Xiamen | Jan 22, 2026
|
|
|
